Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.7213
+0.0003 (0.04%)
At close: Dec 5, 2025, 4:00 PM EST
0.7201
-0.0012 (-0.17%)
After-hours: Dec 5, 2025, 4:10 PM EST
Barinthus Biotherapeutics Revenue
In the year 2024, Barinthus Biotherapeutics had annual revenue of $14.97M with 1,766.46% growth.
Revenue (ttm)
$14.97M
Revenue Growth
+1,766.46%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
29.45M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BRNS News
- 6 weeks ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 2 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 2 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire
- 6 months ago - Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 - Accesswire
- 9 months ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 9 months ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 11 months ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 1 year ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire